Cargando…

A closer look to apathy

INTRODUCTION: Apathy is a neuropsychiatry syndrome, conceptualised as a loss of motivation free of altered consciousness, cognitive impairment or emotional distress, associated with a wide range of brain disorders such as Dementia, Major depression and schizophrenia. Even though under-recognized and...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, D., Martins, R., Polido, F., Cruz, M.D.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475982/
http://dx.doi.org/10.1192/j.eurpsy.2021.1266
_version_ 1784790037496332288
author Silva, D.
Martins, R.
Polido, F.
Cruz, M.D.C.
author_facet Silva, D.
Martins, R.
Polido, F.
Cruz, M.D.C.
author_sort Silva, D.
collection PubMed
description INTRODUCTION: Apathy is a neuropsychiatry syndrome, conceptualised as a loss of motivation free of altered consciousness, cognitive impairment or emotional distress, associated with a wide range of brain disorders such as Dementia, Major depression and schizophrenia. Even though under-recognized and under-diagnosed, apathy hardly appears uncommon. Its reported frequency in various neurologic and psychiatric conditions varies widely, from less than 10 to over 80%, reflecting differences in population characteristics and assessment procedures. OBJECTIVES: The aim of this article is to review the concept of Apathy and clarify its nosology, pathopshysiology and treatment. METHODS: An online bibliographic search was carried out on PubMed and Medline using “Apathy” as a term. RESULTS: The literature reviewed shows that apathy is a multi-dimensional clinical construct with a current definition and validated diagnostic criteria. Analysis reveals that apathy is strongly associated with disruption particularly of anterior cingulate cortex (ACC), ventral striatum (VS) and nucleus accumbens (N acc). Remarkably, these changes are consistent across clinical disorders and imaging modalities, playing a crucial role in normal motivated behaviour. CONCLUSIONS: The neuromodulator dopamine is heavily implicated in ACC and VS. Therapeutically, numerous small studies suggest that psychostimulants, dopaminergics, and cholinesterase inhibitors may benefit those manifesting this syndrome. However, no adequately powered, randomized controlled trials have reported success and no medication have ever been approved for this disorder Further research is needed to help understand the functional neuroanatomy, neuromodulators involved and possible treatment options of this clinical construct.
format Online
Article
Text
id pubmed-9475982
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94759822022-09-29 A closer look to apathy Silva, D. Martins, R. Polido, F. Cruz, M.D.C. Eur Psychiatry Abstract INTRODUCTION: Apathy is a neuropsychiatry syndrome, conceptualised as a loss of motivation free of altered consciousness, cognitive impairment or emotional distress, associated with a wide range of brain disorders such as Dementia, Major depression and schizophrenia. Even though under-recognized and under-diagnosed, apathy hardly appears uncommon. Its reported frequency in various neurologic and psychiatric conditions varies widely, from less than 10 to over 80%, reflecting differences in population characteristics and assessment procedures. OBJECTIVES: The aim of this article is to review the concept of Apathy and clarify its nosology, pathopshysiology and treatment. METHODS: An online bibliographic search was carried out on PubMed and Medline using “Apathy” as a term. RESULTS: The literature reviewed shows that apathy is a multi-dimensional clinical construct with a current definition and validated diagnostic criteria. Analysis reveals that apathy is strongly associated with disruption particularly of anterior cingulate cortex (ACC), ventral striatum (VS) and nucleus accumbens (N acc). Remarkably, these changes are consistent across clinical disorders and imaging modalities, playing a crucial role in normal motivated behaviour. CONCLUSIONS: The neuromodulator dopamine is heavily implicated in ACC and VS. Therapeutically, numerous small studies suggest that psychostimulants, dopaminergics, and cholinesterase inhibitors may benefit those manifesting this syndrome. However, no adequately powered, randomized controlled trials have reported success and no medication have ever been approved for this disorder Further research is needed to help understand the functional neuroanatomy, neuromodulators involved and possible treatment options of this clinical construct. Cambridge University Press 2021-08-13 /pmc/articles/PMC9475982/ http://dx.doi.org/10.1192/j.eurpsy.2021.1266 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Silva, D.
Martins, R.
Polido, F.
Cruz, M.D.C.
A closer look to apathy
title A closer look to apathy
title_full A closer look to apathy
title_fullStr A closer look to apathy
title_full_unstemmed A closer look to apathy
title_short A closer look to apathy
title_sort closer look to apathy
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475982/
http://dx.doi.org/10.1192/j.eurpsy.2021.1266
work_keys_str_mv AT silvad acloserlooktoapathy
AT martinsr acloserlooktoapathy
AT polidof acloserlooktoapathy
AT cruzmdc acloserlooktoapathy
AT silvad closerlooktoapathy
AT martinsr closerlooktoapathy
AT polidof closerlooktoapathy
AT cruzmdc closerlooktoapathy